Literature DB >> 26770310

Transthoracic versus abdominal-transhiatal resection for treating Siewert type II/III adenocarcinoma of the esophagogastric junction: a meta-analysis.

Zhi Zheng1, Jun Cai1, Jie Yin1, Jun Zhang1, Zhong-Tao Zhang1, Kang-Li Wang1.   

Abstract

Our study aimed to explore the differences in short and long-term outcomes about the transthoracic (TH) and abdominal-transhiatal (TH) approaches for treating esophagogastric junction (AEG). A systematic review of PubMed, EMbase, Cochrane Library, China National Knowledge Infrastructure and CBMdisc was performed. All original articles comparing TH with TA were included in the study. Meta-analysis was conducted using odd ratios (OR) and weighted mean differences (WMDs).Thirteen studies including 2489 patients with adenocarcinoma of the esophagogastric junction, with 1050 patients underwent TA and 1437 patients underwent TH were pooled for this study. There were no significant difference between two approaches concerning duration of operation, blood loss, anastomotic leakage and positive of proximal incisal margin. Lymph node excised also showed no significant differences between two procedures in RCTs while in TA group of Non-RCTs, the number of lymph node dissection is higher. TH approach was associated with a longer length of hospital stay and had higher incidence of respiratory and cardiovascular complications and early postoperative mortality. Overall analysis of 1, 3, 5-year survival showed no significant difference between two approaches. Based on the study, TA approach had a positive impact than TH for AEG with respect to respiratory and cardiovascular complications, hospital stay and early mortality rates. There were no significant differences between the two approaches for long-term survival. Therefore, two surgical approaches are acceptable, and the elders with poor cardiopulmonary function, we recommended TA approach for treating it.

Entities:  

Keywords:  Gastric cancer; Siewert type II/III; adenocarcinoma of the esophagogastric junction; meta-analysis; prognosis; surgical resection

Year:  2015        PMID: 26770310      PMCID: PMC4694210     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  45 in total

1.  Comparison of transthoracic and transabdominal surgical approaches for the treatment of adenocarcinoma of the cardia.

Authors:  Bin Zheng; Ying-Bo Chen; Yi Hu; Jun-Ye Wang; Zhi-Wei Zhou; Jian-Hua Fu
Journal:  Chin J Cancer       Date:  2010-08

2.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

Authors:  M K Parmar; V Torri; L Stewart
Journal:  Stat Med       Date:  1998-12-30       Impact factor: 2.373

3.  Surgical management of adenocarcinoma of the cardia.

Authors:  A J Graham; R J Finley; J C Clifton; K G Evans; G Fradet
Journal:  Am J Surg       Date:  1998-05       Impact factor: 2.565

4.  Outcome after transthoracic resection of carcinoma of the oesophagus and oesophago-gastric junction.

Authors:  L S Jensen; H K Pilegaard; E Puho; E Pahle; N C Melsen
Journal:  Scand J Surg       Date:  2005       Impact factor: 2.360

5.  Invited commentary: a critical look at some popular meta-analytic methods.

Authors:  S Greenland
Journal:  Am J Epidemiol       Date:  1994-08-01       Impact factor: 4.897

6.  Esophagogastrectomy for carcinoma of the esophagus and cardia: a comparison of findings and results after standard resection in three consecutive eight-year intervals with improved staging criteria.

Authors:  F H Ellis; G J Heatley; M J Krasna; W A Williamson; K Balogh
Journal:  J Thorac Cardiovasc Surg       Date:  1997-05       Impact factor: 5.209

7.  A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.

Authors:  T N Walsh; N Noonan; D Hollywood; A Kelly; N Keeling; T P Hennessy
Journal:  N Engl J Med       Date:  1996-08-15       Impact factor: 91.245

Review 8.  Transhiatal versus Ivor-Lewis oesophagectomy: is there a difference?

Authors:  R Rindani; C J Martin; M R Cox
Journal:  Aust N Z J Surg       Date:  1999-03

Review 9.  Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification.

Authors:  J Rüdiger Siewert; Marcus Feith; Hubert J Stein
Journal:  J Surg Oncol       Date:  2005-06-01       Impact factor: 3.454

10.  A prospective comparison of transthoracic and transhiatal resection for esophageal carcinoma in Asians.

Authors:  Shah-Hwa Chou; Hung-Yi Chuang; Meei-Feng Huang; Chia-Hua Lee; Harvey Man-Pun Yau
Journal:  Hepatogastroenterology       Date:  2009 May-Jun
View more
  5 in total

1.  Positive esophageal proximal resection margin: an important prognostic factor for esophageal cancer that warrants adjuvant therapy.

Authors:  Yun-Cang Wang; Han-Yu Deng; Wen-Ping Wang; Du He; Peng-Zhi Ni; Wei-Peng Hu; Zhi-Qiang Wang; Long-Qi Chen
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

Review 2.  Current Status and Future Prospects for Esophageal Cancer Treatment.

Authors:  Makoto Sohda; Hiroyuki Kuwano
Journal:  Ann Thorac Cardiovasc Surg       Date:  2016-12-21       Impact factor: 1.520

Review 3.  [Differentiated surgical approach for adenocarcinoma of the gastroesophageal junction].

Authors:  W Schröder; R Lambertz; R van Hillegesberger; C Bruns
Journal:  Chirurg       Date:  2017-12       Impact factor: 0.955

4.  Surgical approach for Siewert type II adenocarcinoma of the esophagogastric junction: transthoracic or transabdominal? -a single-center retrospective study.

Authors:  Zi-Feng Yang; De-Qing Wu; Jun-Jiang Wang; Xing-Yu Feng; Jia-Bin Zheng; Wei-Xian Hu; Yong Li
Journal:  Ann Transl Med       Date:  2018-12

5.  Dorsal Track Control (DTC): A Modified Surgical Technique for Atraumatic Handling of the Distal Esophagus in Esophagojejunostomy.

Authors:  Nadja Lehwald-Tywuschik; Fabian Steinfurth; Feride Kröpil; Andreas Krieg; Hülya Sarikaya; Wolfram Trudo Knoefel; Martin Krüger; Tahar Benhidjeb; Morris Beshay; Jan Schulte Am Esch
Journal:  J Gastric Cancer       Date:  2019-10-23       Impact factor: 3.720

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.